

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 June 2025 (12.06.2025)



(10) International Publication Number
WO 2025/122699 A1

(51) International Patent Classification:

A61K 31/365 (2006.01) C07D 311/78 (2006.01)
A61K 31/122 (2006.01) A61P 35/02 (2006.01)

(21) International Application Number:

PCT/US2024/058597

(22) International Filing Date:

05 December 2024 (05.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/606,581 05 December 2023 (05.12.2023) US

(71) Applicant: **LIN BIOSCIENCE, INC.** [CN/CN]; 36F.,
No.68, Sec.5, Zhongxiao E. Rd., Xinyi Dist., Taipei City,
110 (TW).

(72) Inventors; and

(71) Applicants: **LIN, Tom** [AU/AU]; 7203/1 Barangaroo Av-
enue, Sydney, NSW 2000 (AU). **WANG, Irene** [US/CN];
36F., No.68, Sec.5, Zhongxiao E. Rd., Taipei, 110 (TW).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: CDC7 INHIBITOR COMBINATIONAL THERAPY




FIG. 1

(57) Abstract: The present invention provides a method of treatment and composition for CDC7 inhibitor combinational therapy for treatment of proliferative diseases. In an embodiment, the composition of the present invention comprises a therapeutically effective amount of a combination of a CDC7 inhibitor of the present invention or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents. In an embodiment, the CDC7 inhibitor comprises granaticin B. In an embodiment, the antineoplastic agent comprises azacitidine and venetoclax. The present invention further provides a method of treatment comprising the step of administration to a subject suffering from proliferative disease of any embodiment of the composition of the present invention.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*